Ekf Diagnostics Share Discussion Threads

[hazl] 28/4/2020 13:40

EKF Diagnostics’s Tweets
EKF Diagnostics
@EKFdiagnostics
·
6h
EKF is in the final stages of establishing a UK production line at the Company’s facilities in South Wales, which could produce 12,500 sample collection tubes a day. Devices made at this site will be used in the UK. Read full announcement -

[hazl] 28/4/2020 11:14

I have got these for several reasons but also because I wonder if some of the different virus connected shares, will continue to have longevity, depending on how specific they are.
Whereas EKF already have a thriving business with cash and a valid Covid 19 connection.

[hazl] 28/4/2020 10:21

Biosen and Lactate Scout+ are used by football teams in the English Premier League

[hazl] 28/4/2020 10:19

A DIFFERENT SIDE TO THE COMPANY

[hazl] 28/4/2020 09:41

'EKF Diagnostics is rapidly scaling up production for the US and globally to meet the demand of one of the core components in the COVID-19 molecular testing supply chain, PrimeStore MTM. Sample collection and transport is an essential part of COVID-19 testing as PrimeStore MTM is the first and only US FDA Cleared Microbial Nucleic Acid Storage and Transport Device and was designed for viral pandemics. PrimeStore MTM deactivates the pathogens in the sample, rendering them non-infectious, allowing for safe transport and laboratory handling. Samples collected using this device can also be maintained at ambient temperature for days, eliminating the need for cold chain procedures, and handled at laboratories with a lower biosafety containment rating than is otherwise required. This has the benefit of significantly increasing the number and spread of laboratories able to handle samples. '

from 24 MARCH

[wan] 28/4/2020 09:31

Roche had already significantly expanded testing (to see if you had Coronavirus) -

FDA issued Emergency Use Authorization for the cobas SARS-CoV-2 test (coronavirus) for detection of infection with the virus; test also available in markets accepting the CE mark

Production capacity for cobas SARS-CoV-2 test ramped up massively

The next phase of testing capacity ramp-up, serology testing (to see if you have had Coronavirus), is a very important factor globally. The capacity ramp for this is being put in to place and a significant increase in testing is imminent -

Anti-SARS-CoV-2 serology test to detect antibodies in people exposed to SARS-CoV-2 in late stage development with availability aimed for early May. Monthly production is ramped up to high double-digit million tests by June with further scale up as fast as possible.

Source Roche -

[hazl] 28/4/2020 09:16

Christopher Mills, Non-Executive Chairman of EKF, commented:

"With good cash resources and a business which is growing strongly, EKF has moved into a phase where we are confident that we can provide an income for shareholders and the prospect of significant upside from our relationships with MSIP and others. Trading in 2020 to date has been satisfactory and in line with management expectations.

"Despite these difficult times, EKF is in a very strong position. We have a substantial net cash balance, continuing solid positive cash flow and the business remains robust. We see significant opportunities globally, particularly within the USA. Being a medical device company focussing on tests monitoring diabetes and haemoglobin, both conditions putting patients in higher risk categories should they contract COVID-19, EKF is well positioned to assist the medical and scientific community. "

[hazl] 28/4/2020 08:28

I particularly liked the announcement yesterday wan.
Looks as though it could lead to a lot more contracts to me.

[hazl] 28/4/2020 08:09

Ha mid price lower than bid.....8-)

[hazl] 28/4/2020 08:08

EKF Diagnostics Holdings plc (AIM: EKF), the AIM quoted point-of-care business, announces that further to yesterday's announcement regarding the significant increase in manufacturing demand for the PrimeStore MTM sample collection device, the Company is in the final stages of establishing a UK production line at the Company's facilities in Penarth, South Wales, which could produce 12,500 sample collection tubes a day. Devices made at this site will be used in the UK.

Global demand for the PrimeStore MTM device has increased significantly due to COVID-19. The PrimeStore MTM sample collection device, deactivates viruses, bacteria, fungi and mycobacterium tuberculosis allowing safe sample handling and transport, greatly reducing risk of infection. The device was invented in 2006 in preparation for a worldwide pandemic and is designed to de-activate pathogen rapidly and stabilise the RNA for up to four weeks with no requirement for cold storage. In the case of COVID-19, by inactivating the virus testing can now take place outside of containment facilities opening up capacity in more testing laboratories.

The Company expects to ship first products from the new production line in Penarth in mid-May, if not sooner, and will provide further updates to shareholders as appropriate. Following the successful establishment of the production line in Wales, the Company will look to increase manufacturing capacity for the PrimeStore MTM device further, via its two sites in Germany. This will increase the capacity to supply sample collection devices into mainland Europe.

The establishment of the production line will see EKF increase staffing levels at the Penarth facility with 12 temporary contracts, with these positions being filled by local workers, recently out of work due to the impact of the pandemic or on leave from their studies.

Commenting, Julian Baines, CEO of EKF Diagnostics, said: "We are very pleased to be supporting international efforts to monitor and limit the spread of Coronavirus globally. The newly established production line in South Wales will help us to meet the growing demand for these sample collection kits, to ensure that COVID-19 samples can be handled and transported without the need for expensive refrigeration or fear of contamination.

"Whilst the majority of these kits that we make are being sold and used in volume across the US, the sample collection kits are currently under review for use in the UK and our new manufacturing capability in Penarth will allow us to readily supply an effective tool for supporting the ramp up in COVID-19 testing which is urgently needed in the UK."

[hazl] 28/4/2020 08:04

Pulling out late trades already I see....from yesterday I would imagine.

[wan] 28/4/2020 08:03

Super news today from EKF!

And it beat me to it, as my previous research was based on the explosion of COVID-19 tests in the US and subsequent usage, and hence I had actually started to look at the situation in Europe. EKF's UK and German sites were on my radar.

There is every reason that the same demand and rationale, in terms of the need for a significant increase in manufacturing capacity, will apply to the UK and indeed Europe.

In my view, the ramifications of the COVID-19 situation means that being able to react and importantly, 'effectively' respond to outbreaks and pandemics, should mean that appropriate manufacturing capacity and maintaining global stock levels is likely to become a permanent feature.

[hazl] 28/4/2020 07:46

I dipped a toe in here yesterday.

I don't know how I missed it before!

Looks an interesting company.

[imjustdandy] 27/4/2020 15:16

Sold into - plenty on offer

[meijiman] 27/4/2020 08:40

Well I'm very pleased to be a holder here. now wishing I had not sold some under 10p.
Is the Singer research available...sounds like you have to know someone who works there?

[supertag] 27/4/2020 08:12

Yep, looking good.

[bubbleandleek] 27/4/2020 08:06

I’ve been following this company for a while now and also the list of companies on AIM that have announced C-19 measures over the last few weeks. I can’t help but think that this is hugely undervalued if you look at the likes of AVACTA, NOVACYT, OMEGA DIAGNOSTICS etc that are all loss making and hanging their hats on their testing equipment for C-19. Their share prices have gone ballistic on ‘what if’ scenarios but EKF are actually putting numbers to their updates. I’ve managed to have a quick read of the singers note out this morning (via a trader friend of mine!) and the numbers don’t make sense. They are factoring in $4m this year for EKF’s re-agent but if you read the RNS it clearly states that $3m is for May alone ($1m already received last month). This in my view will continue month on month not just for this year. The device/reagent already has FDA and CE approval as well.... my view is this should be trading in the 50’s not the low 30’s. This company has made solid statements backed up by numbers unlike the majority of the AIM companies that have said they ‘may’ have the testing equipment needed. The valuation here is solid I believe. Any thoughts appreciated?

[wan] 27/4/2020 07:30

Today's update of a significant increase in COVID-19 related demand aligns with what I hoped I was seeing, and that that demand would hopefully offset any weakness elsewhere. So, it is very good news that we have confirmation of such, and that current trading has been in excess of managements expectations and that EKF looks set to deliver full year results in excess of managements expectations.

[time_lord] 27/4/2020 07:27

Also, I found this tweet the other day, which is rather intriguing:

"Shout out to the guys at EKF Diagnostics busy looking into COVID tests."

[time_lord] 27/4/2020 07:24

RNS out this morning - sounds promising:

[wan] 24/4/2020 08:33

STAT-Site WB link added to the above post.